The FDA has authorized osimertinib, also referred to as Tagrisso, which is a cutting-edge treatment, for the therapy for progressive non-small cell lung cancer (NSCLC).Osimertinib belongs to the class of drugs called TKIs (TKIs), which focus on particular enzymes that facilitate the growth and dissemination of malignant cells.By inhibiting these enzymes, osimertinib assists in retarding the advancement of the disease and improving the lifestyle quality for patients.Osimertinib operates by targeting the EGFR (epidermal growth factor receptor) mutation, a characteristic present in about 10-15% of NSCLC patients.This mutation causes unchecked cell…
